The American Urology Association (AUA) and the Society of Urologic Oncology (SUO) recently updated their Advanced Prostate Cancer guideline. The 2026 update follows and replaces the previous version from 2023. As the management of advanced prostate cancer evolves, the societies develop evidence-based guideline statements to assist in clinical decision-making, updating them periodically.
The AUA/SUO Advanced Prostate Cancer guideline focuses on the stages of advanced prostate cancer, ranging from PSA recurrence after exhaustion of local treatment options to widespread metastatic disease. The update reflects a literature search of studies published from March 16, 2022, through August 26, 2025.
Below, we have outlined key updates from the 2026 AUA Advanced Prostate Cancer guideline update. Refer to the full-text version for the most thorough look at the updates and included recommendations.
- In the Early Evaluation and Counseling section, a fourth statement was regarding clinicians offering germline testing and somatic tumor testing.
- In the Biochemical Recurrence without Metastatic Disease after Exhaustion of Local Treatment Options section, statement six (formerly statement five) was updated regarding imaging guidance.
- Within the same section, statement seven (formerly statement six), was updated regarding imaging guidance.
- Corresponding references were adjusted or added for the three of the previous updates.
- In statment eight, within the Biochemical Recurrence[...] section, statement eight (formerly statement seven) was updated to include risk stratification guidance.
Sign up for alerts and stay informed on the latest published guidelines and articles.